−3.1473 EUR
−3.35 M EUR
0.00 EUR
745.44 K
About Epigenomics AG
Sector
Industry
Website
Headquarters
Heidelberg
Founded
2000
ISIN
DE000A37FT41
FIGI
BBG000F1MBK9
Epigenomics AG is a molecular diagnostics company, which engages in the development and commercializing of proprietary products for the screening and diagnosis of cancer. It offers Epi proColon, a blood-based test for the early detection of colorectal cancer; Epi proLung, a confirmatory test that aids in the diagnosis of lung cancer, Epi BiSKit, a kit for the preparation of purified, bisulfite-converted DNA and, HCCBloodTest, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma. The company was founded by Oliver Schacht, Christian Piepenbrock, Kurt Berlin, Jörn Walter, and Ivo G. Gut in 1998 and is headquartered in Berlin, Germany.
Related stocks
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange Epigenomics AG stocks are traded under the ticker ECX.
Yes, you can track Epigenomics AG financials in yearly and quarterly reports right on TradingView.
ECX net income for the last half-year is −204.00 K EUR, while the previous report showed −2.56 M EUR of net income which accounts for 92.02% change. Track more Epigenomics AG financial stats to get the full picture.
No, ECX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ECX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Epigenomics AG stock right from TradingView charts — choose your broker and connect to your account.